Cargando…
Bisphosphonates as antimyeloma drugs
In patients with symptomatic multiple myeloma (MM), bisphosphonate (BP) treatment has been widely used to prevent bone loss and preserve skeletal health because of its proven effects on inhibiting osteoclast-mediated bone resorption. In addition to their effects on osteoclasts, it is becoming increa...
Autores principales: | Modi, N D, Lentzsch, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364444/ https://www.ncbi.nlm.nih.gov/pubmed/22005788 http://dx.doi.org/10.1038/leu.2011.282 |
Ejemplares similares
-
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
por: D'Souza, Criselle, et al.
Publicado: (2021) -
Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects
por: Li, Shirong, et al.
Publicado: (2023) -
Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy
por: Zhang, Yanyu, et al.
Publicado: (2020) -
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
por: Xu, Li, et al.
Publicado: (2020) -
Liposome-Encapsulated
Melphalan Exhibits Potent Antimyeloma
Activity and Reduced Toxicity
por: Lin, Zhimei, et al.
Publicado: (2022)